Hiroshi Nagabukuro
Vorstandsvorsitzender bei ARTham Therapeutics, Inc.
Aktive Positionen von Hiroshi Nagabukuro
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
ARTham Therapeutics, Inc.
 ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Direktor/Vorstandsmitglied | 01.07.2018 | - |
| Vorstandsvorsitzender | 01.07.2018 | - | |
| Präsident | 01.07.2018 | - |
Karriereverlauf von Hiroshi Nagabukuro
Statistik
International
| Japan | 2 |
Operativ
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| President | 1 |
Sektoral
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
ARTham Therapeutics, Inc.
ARTham Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million. | Health Technology |
- Börse
- Insiders
- Hiroshi Nagabukuro
- Erfahrung
